{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-041172","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.709234+00:00","generated_at":"2026-06-21T19:27:41.227505+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Galectin reports Q3 2022 net loss $8.6M; NAVIGATE trial 88% enrolled","bullets":["Net loss $8.6M ($0.14/sh) for Q3 2022, unchanged from Q3 2021.","Cash $15.8M; plus $60M credit line; expects funding through Dec 2024.","NAVIGATE trial: 279 of 315 patients randomized, 74 in screening; target full enrollment around end-2022.","FDA allowed IND for belapectin + Keytruda in head and neck cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-041172","json":"https://secwatch.observer/filing/0001140361-22-041172.json","markdown":"https://secwatch.observer/filing/0001140361-22-041172.md","text":"https://secwatch.observer/filing/0001140361-22-041172.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036122041172/0001140361-22-041172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036122041172/brhc10044046-8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:27:41.227505+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b246930adc9a7f03e4a6d8d804abbb9b086eb6c","claim":"GALECTIN THERAPEUTICS INC reported the three months ended September 30, 2022 results: net income $8.6 million, EPS ($0.14) per share.","evidence_excerpt":"For the three months ended September 30, 2022, the Company reported a net loss applicable to common stockholders of $8.6 million, or ($0.14) per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036122041172/0001140361-22-041172-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Net income","value":"$8.6 million"},{"label":"EPS","value":"($0.14) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}